Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial

Journal of the American Medical Association

Volumn 288, Issue 19, 2002, Pages 2411-2420

  Steinhubl, Steven R ^a   Berger, Peter B ^b   Tift Mann III, J ^c   Fry, Edward T A ^d   DeLago, Augustin ^e   Wilmer, Charles ^f   Topol, Eric J ^g  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c WAKEMED HEALTH AND HOSPITALS   (United States)

^d ST VINCENT HOSPITAL   (United States)

^e ALBANY MEDICAL CENTER   (United States)

^f ATLANTA MEDICAL CENTER   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEATH; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NORTH AMERICA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADMINISTRATION, ORAL; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CEREBROVASCULAR ACCIDENT; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; SURVIVAL ANALYSIS; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 0037145863     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.19.2411     Document Type: Article

References (25)

1. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: The Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) Study. Circulation. 1998;98:1597-1603.
2. Leon MB, Bairn DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens following coronary artery stenting. N Engl J Med. 1998;339:1665-1671.
3. Schomig A, Neumann F, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after placement of coronary-artery stents. N Engl J Med. 1996;334:1084-1089.
4. Urban P, Macaya C, Rupprecht H-J, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation. 1998;98:2126-2132.
5. Steinhubl SR, Lauer MS, Mukherjee DP, et al. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. J Am Coll Cardiol. 1998;32:1366-1370.
6. Steinhubl SR, Ellis SG, Wolski K, Lincoff AM, Topol EJ. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: Data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation. 2001;103:1403-1409.
7. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-1894.
8. Mehta S, Yusuf S, Peters R, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet. 2001;358:527-533.
9. van Dornburg RT, Foley DP, de Jaegere PPT, et al. Long term outcome after coronary stent implantation: A 10 year single centre experience of 1000 patients. Heart. 1999;82(suppl 11):1127-1134.
10. Thel MC, Califf RM, Tardiff BE, et al. Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Am J Cardiol. 2000;85:427-434.
11. Schulen H, Kastrati A, Dirschinger J, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation. 1998;98:104-111.
12. Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: Kinetic profile of pharmacodynamic responses in healthy subjects. Semin Thromb Hemost. 1999;25(suppl 2): 15-19.
13. Seyfarth H-J, Koksch M, Roethig G, et al. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am Heart J. 2002; 143:118-123.
14. Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. 2001;85:92-93.
15. Helft G, Osende JI, Worthley SG, et al. Acute antithrombotic effect of front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol. 2000;20:2316-2321.
16. Berger PB, Steinhubl SR. Clinical implications of Percutaneous Coronary Intervention-Clopidogrel in Unstable angina to prevent Recurrent Events (PCI-CURE) study: A US perspective. Circulation. 2002;106:2284-2287.
17. Bonz AW, Lengenfelder B, Strotmann J, et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J Am Coll Cardiol. 2002;40:662-668.
18. Chew D, Bhatt D, Robbins M, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation. 2001;104:992-997.
19. Chew DP, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol. 2001;88:672-674.
20. Page CP. Platelets as inflammatory cells. Immunopharmacology. 1989;17:51-59.
21. Neumann F-J, Marx N, Gawaz M, et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation. 1997;95:2387-2394.
22. Klinkhardt U, Graff J, Harder S. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in human ex vivo in vitro model. Clin Pharmacol Ther. 2002;71:176-185.
23. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
24. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002;90:625-627.
25. Peters RJG, Zao F, Lewis BS, Fox KAA, Yusuf S, for the CURE Investigators. Aspirin dose and bleeding events in the CURE study. Eur Heart J. 2002;4(suppl):510.